Meet Acumetis at ISPOR

Acumetis will be attending ISPOR U.S. 2026 in Philadelphia, the leading global conference for Health Economics and Outcomes Research (HEOR) and market access strategy.

With more than 4,000 global attendees across 70+ countries, ISPOR brings together stakeholders across pharma, biotech, payers, HTA bodies, academia, and policy to explore how evidence, value, and policy intersect to shape real-world access decisions.

Why Meet with Acumetis

Acumetis partners with life sciences organizations to translate complex clinical and real-world evidence into clear, decision-relevant strategies that support pricing, reimbursement, and access.

At ISPOR, we are especially focused on how policy changes including Most Favored Nation (MFN) dynamics and broader pricing reform are reshaping global access strategy and decision-making. We are focused on helping teams navigate a rapidly evolving evidence and policy landscape, where expectations from HTA bodies, payers, and regulators continue to increase, and where decision-making is often shaped by uncertainty, data limitations, and shifting comparators.

Our team will also be leading discussions and demonstrations focused on MFN exposure and its implications for pricing, reimbursement, and global market access.

Our approach is grounded in connected insights and practical innovation, helping teams move beyond analysis to action, de-risk decisions, and drive measurable outcomes in increasingly complex environments.

Our conversations will center on:

• Translating evidence into value narratives – Developing robust, defensible value stories that resonate with payers and HTA bodies across markets
• Adapting to evolving HTA and payer expectations – Aligning evidence generation strategies with changing requirements, including Joint Clinical Assessments (JCA) and global access considerations
• Managing uncertainty in evidence and decision-making – Supporting teams in making confident decisions despite data limitations, comparator challenges, and shifting policy dynamics
• Connecting HEOR, Medical, and Market Access strategy – Ensuring cross-functional alignment to strengthen evidence planning, value communication, and access outcomes
• Applying real-world evidence to support access decisions – Moving from data availability to “decision-grade” evidence that can withstand payer and regulatory scrutiny

We work as a proactive, collaborative, and accountable partner, supporting teams not just in defining strategy, but in executing against it, helping leaders move forward with clarity and confidence.

As a multi-capability partner, Acumetis is purpose-built to help organizations navigate complexity and position themselves to succeed in an increasingly competitive and opportunity-rich landscape.

Where to Find Us

May 17–20, 2026

Pennsylvania Convention Center, Philadelphia

Booth #811

Visit our team at Booth #811 to explore our MFN Exposure Assessment tool and engage in discussions on how policy and evidence are shaping access strategy in 2026.

Acumetis at ISPOR 2026

At ISPOR 2026, Acumetis will be actively engaging with attendees through a series of discussions and demonstrations focused on policy, pricing, and access strategy.

Our onsite activities will include:

• MFN-focused lunch and learn sessions exploring the evolving policy landscape
• Demonstrations of the MFN Exposure Assessment tool, designed to help organizations evaluate risk and strategic impact
• Discussions on global pricing and market access strategy, including the implications of IRA, MFN, and other policy shifts
• Real-world evidence applications to support reimbursement and access decision-making

Key Topics We’re Discussing

• U.S. and global pricing reform (IRA, MFN, and evolving policy dynamics)

Understanding how policy changes—including MFN—are reshaping pricing, reimbursement, and global access strategy

• Decision-grade real-world evidence (RWE)
  Advancing from data generation to evidence that is credible, reproducible, and accepted in payer and HTA decision-making
• Evolving HTA and payer expectations
  Adapting to increasing scrutiny around comparators, endpoints, and value frameworks, including the impact of Joint Clinical Assessments (JCA)
• Aligning HEOR, Medical, and Market Access strategy
  Strengthening cross-functional integration to ensure evidence plans translate into effective value communication and access outcomes
• Applying AI and advanced analytics in HEOR
  Exploring how AI is being used to support evidence synthesis, modeling, and decision-making in real-world settings

Who You’ll Meet

Karl Freemyer – Market Access & Policy Expert  
Leader in global pricing and access strategy with deep experience in navigating policy-driven market dynamics.

Andy Revel – Market Access Leader  
Focuses on global access strategy and commercialization, supporting organizations in translating evidence into actionable access decisions.

Schedule a meeting with the Acumetis team at Booth #811 during ISPOR 2026 to discuss your current priorities across HEOR, market access, and policy strategy.